Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology

F. Pacini1,10 · E. Brianzoni2 · C. Durante3 · R. Elisei4 · M. Ferdeghini5 · L. Fugazzola6,7 · S. Mariotti8 · G. Pellegriti9

Received: 8 July 2015 / Accepted: 28 July 2015 / Published online: 12 August 2015 © The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract Post-surgical ablation of thyroid remnant with radioactive iodine (RAI) in differentiated thyroid cancer (DTC) is aimed to destroy any thyroid remnant in the thyroid bed (remnant ablation) and any microscopic foci of cancer cells eventually present within the thyroid remnant (adjuvant therapy). The present text is an attempt to offer practice guidelines for the indication of thyroid ablation and the preparation of DTC patients considering the latest achievement in the field and the changing epidemiology of DTC observed in the last 10 years.

Methodology The executive committee of the Italian Society of Endocrinology appointed a task force of thyroid cancer expert including Nuclear Medicine Physicians and Endocrinologists to provide a consensus on the post-surgical ablation in thyroid cancer patients. The task force had no conflict of interest and had no commercial support. A number of specific topics were selected and the members selected relevant papers by searching in the Pubmed for articles published from 2000 to January 2015. Selected studies were categorized by level of evidence, and the recommendations were graded according to the level of evidence as high (A), moderate (B), or low (C).

Keywords Radioiodine · Thyroid ablation · Thyroid cancer · Thyroglobulin · rhTSH

Introduction

Post-surgical ablation of thyroid remnant with radioactive iodine (RAI) (remnant ablation) in differentiated thyroid cancer (DTC) is aimed to facilitate the early detection of recurrence based on serum thyroglobulin (Tg) measurement and/or RAI whole-body scan (WBS) and to obtain a post-therapy WBS, whose results may change the initial staging by identifying previously undiagnosed disease. In addition, RAI ablation may represent an adjuvant therapy by cleaning persistent microscopic foci of cancer which can be present in the thyroid remnant especially in papillary thyroid cancer (PTC) that are frequently multifocal. While the first aim, remnant ablation, is related to follow-up in any patient regardless of his specific risk, the second one, adjuvant therapy, is advocated as a tool to reduce the rates of disease recurrence or cause-specific mortality [1], and thus its use must be justified according to a real risk of recurrence. Indeed, in patients at the lowest risk for
recurrence and mortality several studies have shown no benefit of remnant ablation [2]. Benefit becomes evident in patients considered at intermediate [3] or high risk, particularly in terms of reduced recurrence rate and possibly of reduced mortality.

Based on this consideration, several authoritative guidelines have restricted the indication for RAI ablation to specific categories of patients considered at significant risk of recurrence or death. Since selection of patients for thyroid ablation is not the aim of this guideline, we refer to them for further reading.

Here we will limit our discussion to the choice of the most appropriate activity of $^{131}$I (low or high) to be used whenever thyroid ablation has been decided, including the definition of successful thyroid ablation and the method of preparation for RAI administration.

**Definition of successful remnant ablation**

In the past, successful remnant ablation was defined as the absence of visible RAI uptake on a diagnostic RAI WBS performed 6–12 months after remnant ablation. With the introduction of serum Tg measurement and neck ultrasound in clinical practice, the use of performing diagnostic WBS has been largely abandoned. Indeed, both serum Tg determination [4–8] and neck sonography examination [9] are much more sensitive compared to diagnostic WBS in detecting the existence of persistent or recurrent disease [4–8]. Nowadays, the most accepted definition of successful thyroid ablation is an undetectable stimulated serum Tg (or an undetectable basal serum Tg if using ultra-sensitive Tg assays) combined with undetectable serum anti-thyroglobulin antibodies (TgAb) and a negative neck ultrasound.

TgAb are commonly identified in patients with differentiated follicular cell-derived thyroid cancer. Their frequency in patients with DTC is approximately 20–25 % [10]. In case of positive TgAb, serum Tg cannot be used as a predictor of ablation and we have to rely on neck ultrasound and on the trend of serum Tg. A diagnostic WBS may be considered in this setting. Antibody levels may serve as a surrogate biochemical marker of disease persistence and response to therapy. However, the timing of testing and the duration to see a maximal response appear to differ from Tg levels in patients without TgAb. There may be an initial transient rise in TgAb titer after radioactive iodine (RAI) treatment [11]. Also, it has been shown that the eventual disappearance of TgAb takes approximately 2–3 years on average. Complete ablation of thyroid tissue with its antigenic components results in the disappearance of antibodies to all major thyroid antigens [10–12].

**Preparation for RAI ablation**

Remnant ablation has been traditionally performed after thyroid hormone withdrawal to increase endogenous thyroid-stimulating hormone (TSH) to levels sufficient to induce robust RAI uptake in thyroid cells. Empirically, it is estimated that a TSH of >30 mU/L is a good cut off [13], but no comparative study has ever been done to document this assumption.

For thyroid hormone withdrawal, two possible approaches are used: switch from levothyroxine (LT$_4$) to triiodothyronine (LT$_3$) for some weeks [5, 6] and then stop LT$_3$ for 2 weeks, or stop LT$_4$ for 3–4 weeks without switching to LT$_3$. These two methods have not been compared in terms of better outcomes of ablation.

Since several years, the alternative way of preparation for RAI ablation is the administration of exogenous recombinant human TSH (rhTSH), after a prospective, multicenter, randomized study demonstrated that $^{131}$I remnant ablation with 100 mCi was equally effective after rhTSH stimulation or thyroid hormone withdrawal [14]. In another study, ablation rates were similar with either withdrawal or preparation with rhTSH using 50 mCi of $^{131}$I [15]. Additional evidence that preparation with thyroid hormone withdrawal or rhTSH has the same ablation outcome using both high or low radioiodine doses has been provided in two prospective randomized multicenter studies, one in France and one in the UK [16, 17]. In addition, short-term recurrence rates have been found to be similar in patients prepared with thyroid hormone withdrawal or rhTSH [18, 19]. The preparation with rhTSH significantly improves quality of life [14, 20], and reduces both whole-body irradiation [21, 22] and hospitalization time [23]. A recent meta-analysis confirms the above results [24]. Nowadays, the use of rhTSH is approved for remnant ablation, with any 131I dose, both in the United States and Europe.

**Recommendation 1**

Patients undergoing RAI ablation should be preferentially prepared by rhTSH administration. Thyroid hormone withdrawal may be considered whenever rhTSH is not available or not affordable. Recommendation rating: A.

**Which is the best activity of $^{131}$I to be employed for post-surgical thyroid remnant ablation**

Although there is a trend toward higher ablation rates with higher activities [25, 26], activities between 30 and 100 mCi of $^{131}$I generally show similar rates of successful remnant ablation [27–30]. A randomized study using preparation...
with rhTSH showed that ablation rates were comparable with 50 mCi compared to 100 mCi [31]. A prospective, randomized study performed in 160 patients, comparing ablation with 30 and 100 mCi, after preparation with thyroid hormone withdrawal, found no difference in both the ablation rate and in the rate or recurrence during follow-up [32]. Recently, two prospective randomized studies in very large number of patients conducted in France and in the United Kingdom found no significant difference in the remnant ablation rate using 30 or 100 mCi of $^{131}$I, either after preparation with thyroid hormone withdrawal or rhTSH [16, 17]. It is worth noting, that these two studies included not only low-risk patients, but also patients at intermediate risk of recurrence, including those showing minimal extrathyroidal extension of the primary tumor [17] or lymph node metastases [16, 17]. Also in this category the authors found no difference between low- and high-RAI doses in terms of ablation success rates. This finding has been confirmed in a retrospective study including only patients at intermediate risk, treated with low- and high-RAI activities [33]. In this study, the authors were also able to demonstrate that, with regard to recurrences or deaths, the long-term outcome was not affected by the ablation dose (low or high). Concerning the issue of the follow-up of patients treated with low activity of 131-I and rhTSH or LT4 withdrawal, a recent study [19] showed that in 10 years of follow-up, the rate of recurrence was as low as expected (3.5 %) and similar in both groups. Moreover, the final outcome of these patients was similar at the end of follow-up (Table 1).

No definite studies are available in pediatric patients. For every age patients, some authors have suggested to use a lesion dosimetry or to give the highest dose administrable based on the radiation exposure to the critical organs at risk, especially in high-risk group; others suggest empiric dosage and others an activity based on the patient’s body weight [34–37].

### Recommendation 2

The minimum activity (30 mCi) necessary to achieve successful remnant ablation should be utilized, particularly in patients at low risk and intermediate risk. Recommendation rating: B.

### Recommendation 3

In patients considered at high risk for recurrence, or if residual microscopic disease is suspected or documented, higher activities (100 mCi or more) should be considered. Recommendation rating: C.

| Table 1 Guidelines for radioiodine thyroid ablation | Recommendation | Rating |
|---------------------------------------------------|----------------|--------|
| Preparation for RAI ablation                      | 1. Patients undergoing RAI ablation should be preferentially prepared by rhTSH administration [14, 16, 17] | A |
| Which is the best activity of $^{131}$I to be employed for post-surgical thyroid remnant ablation | 2. The minimum activity (30 mCi) necessary to achieve successful remnant ablation should be utilized, particularly in patients at low risk and intermediate risk [31–33] | B |
|                                                   | 3. In patients considered at high risk for recurrence, or if residual microscopic disease is suspected or documented, higher activities (100 mCi or more) should be considered [40] | C |
| Diagnostic RAI scanning before ablation           | 4. Pre-ablation diagnostic scans are seldom informative as far as the decision to ablate is concerned. They may be considered when a sustained suspicion of local or distant metastases is present to better define the activity of RAI to be administered or in patients with elevated levels of serum TgAb [38, 40–42] | C |
| Post-operative serum Tg levels and neck US        | 5. Post-operative serum Tg levels (in the absence of serum TgAb) and neck US may give additional information regarding the need for ablation and the radioiodine dose to be administered [47, 48] | C |
| Is a low-iodine diet necessary before ablation?    | 6. At least in countries with mild or moderate iodine deficiency, there is no need to prescribe a low-iodine diet before remnant ablation. Avoidance of iodine-containing drugs or contrast agents is mandatory [53] | B |
| Post-therapy WBS after remnant ablation            | 7. A post-therapy WBS is recommended following remnant ablation. This is typically done 3–7 days after the therapeutic dose is administered [54, 55] | A |
doses both to target lesions and to non-target organs (salivary glands).

**Should a diagnostic RAI scanning be performed before ablation? Should post-surgical serum Tg levels be considered in decision making?**

A diagnostic RAI WBS provides information on the presence of iodine-avid thyroid tissue, which may represent the normal thyroid remnant or the presence of residual disease. There is an increasing trend to avoid diagnostic RAI scans because of its low impact on the decision to ablate, and because of concerns over 131I-induced stunning of normal thyroid remnants [39] and distant metastases from thyroid cancer [40–42]. The alternative radiopharmaceutical for staging, 123I, is not readily available and has a short half-life. [43–45].

**Recommendation 4**

Pre-ablation diagnostic scans are seldom informative as far as the decision to ablate is concerned. They may be considered when a sustained suspicion of local or distant metastases is present to better define the activity of RAI to be administered or in patients with elevated levels of serum TgAb. In any case, diagnostic scans should be performed using tracer doses of 123I (if available) or low 131I activity (1–2 mCi). In the last case, the therapeutic activity should be delivered within 72 h of the diagnostic activity to avoid stunning. Recommendation Rating: C.

**Post-operative serum Tg levels and neck US**

Some studies investigating the clinical significance of post-operative serum Tg levels have shown that low post-operative levels of non-stimulated Tg does not exclude persistent disease [46]. However, serum Tg levels may be useful for the indication of 131I activity to be delivered [47] and may represent a significant prognostic marker [48, 49].

Similar prospective information may be derived from the execution of neck US before ablation. US should be performed to check the central and lateral compartments of the neck whenever a cancer is fortuitously discovered at histology, or a preoperative US has not been done or in the presence of high pre-ablation serum Tg values.

**Recommendation 5**

Post-operative serum Tg levels (in the absence of serum TgAb), and neck US may give additional information regarding the need for ablation and the radioiodine dose to be administered. Recommendation Rating C.

**Is a low-iodine diet necessary before remnant ablation?**

Contamination with stable iodine might theoretically influence the uptake of diagnostic or therapeutic doses of RAI [50–52]. Based on this assumption, several centers advocate preparation of the patients with a low-iodine diet and recommend avoiding iodine contamination (intravenous contrast agents, amiodarone, or other iodine-containing drugs) prior to RAI therapy. However, no prospective study has ever determined the cut off at which interference may actually occur. In a retrospective study, aimed to compare different levels of urinary iodine excretion on the results of thyroid ablation in patients not prepared with low-iodine diet, the authors found no influence of different levels of urinary iodine on the outcome of thyroid ablation up to urinary iodine levels exceeding 350 µg/day of dietary iodine. In addition, the median level of iodine urinary content in Italy is as low as in mild iodine-deficient countries [53] and thus, there is no reason to limit the diet and the use of iodized salt in our country. In any case, measurement of urinary iodine excretion (when available) before remnant ablation may help in detecting the few cases with significant iodine contamination.

**Recommendation 6**

At least in countries with mild or moderate iodine deficiency, there is no need to prescribe a low-iodine diet before remnant ablation. Avoidance of iodine-containing drugs or contrast agents is mandatory. If a suspicion of iodine contamination exists, iodine excretion should be evaluated starting from 20 to 30 days after the withdrawal of the iodine-containing drug or the contrast agent injection. Recommendation Rating: B.

**Post-therapy WBS after remnant ablation**

It is recommended to perform a post-therapy WBS within 1 week after RAI therapy. This imaging technique is of paramount importance in confirming the presence and the extent of the thyroid remnant and may disclose the presence of unsuspected metastatic foci in 10–26 % of the cases [55], thus allowing the reclassification of the disease stage [56]. Whenever possible, a SPECT-CT can be useful instead of a planar WBS to better define the neck uptake and distinguish the remnant from local lymph node or paratracheal tumor [57].
Recommendation 7

A post-therapy WBS is recommended following RAI remnant ablation. This is typically done 3–7 days after the therapeutic dose is administered. Recommendation Rating: A.

Compliance with ethical standards

Conflict of interest No conflict of interest.

Ethical approval This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent No informed consent.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Reiners C, Sanchez Franco F, Smit J, Wiersinga W (2005) Post-surgical use of radiiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol 153:651–659
2. Hay ID (2006) Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol 94:692–700
3. Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA (2015) Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate risk papillary thyroid cancer. J Clin Endocrinol Metab 100(4):1529–1536
4. Mazzaferrari EL, Kuos RT (2002) Is diagnostic iodine-131 scanning with recombinant human TSH (rhTSH) useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 87:1490–1498
5. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT (2002) Clinical comparison of whole-body radioidine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 12:37–43
6. Wartofsky L (2002) Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. Thyroid 12:583–590
7. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Todde D, Pinchera A (2002) Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum thyroglobulin levels after initial treatment. J Clin Endocrinol Metab 87:1499–1501
8. Toriglione M, Crocetti U, D’Almois L, Bonfoti N, Di Giorgio A, Moloni S, Valle G, Fruscianti V, Bisceglia M, Filetti S, Schlumberger M, Trischitta V (2003) Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocrinol 148:19–24
9. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Todde D, Grasso L, Pinchera A (2003) Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3668–3673
10. Ringel MD, Nahban F (2013) Approach to follow-up of the patient with differentiated thyroid cancer and positive anti thyroglobulinantibodies. J Clin Endocrinol Metab 98(8):3104–3110
11. Gorges R, Maniecki M, Jentzen W et al (2015) Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol 153(1):49–55
12. Chiovato L, Latrro F, Braverman LE, Pacini F, Capezzone M, Masserini L, Grasso L, Pinchera A (2003) Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 139:346–351
13. Edmonds CJ, Hayes S, Kermode JC, Thompson BD (1977) Measurement of serum TSH and thyroid hormones in the management and treatment of thyroid carcinoma with radiiodine. Br J Radiol 50:799–807
14. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinare E, Eliseie R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lasman M, Reiners C (2006) Radiiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of a randomized, controlled study. J Clin Endocrinol Metab 91:926–932
15. Chianelli M, Todino V, Graziano F, Panunzi C, Pace D, Guglielmi R, Signore A, Papini E (2009) Low dose (2.0 GBq; 54 mCi) radiiodine postsurgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low risk patients. Eur J Endocrinol 160:431–436
16. Schlumberger M, Catargi B, Ph D, Borget I, Deandres D, Zerdoud S, Brijdi B, Bardet S, Leenhardt L, Bastie D, Schuartz C, Vera P, Morel O, Benisy D, Bourmaud C, Bonichon F, Dejax C, Toubert ME, Leboulleux S, Ricard M, Benhamou E (2012) Strategies of radioiodine ablation in patients with low-risk thyroid cancer. NEJM 366:1663–1673
17. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklin JA, John R, Nutting CM, Newbold K, Lemon C, Garrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan A, Alvarez P, Beare S, Forsyth S, Kadelayal L, Hackshaw A (2012) Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. NEJM 366:1674–1685
18. Tuttle RM, Broklin M, Omry G, Martorella AJ, Larson SM, Grewal RK, Fleisher M, Robbins RJ (2008) Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 49:764–770
19. Molinaro E, Giani C, Agate L, Biagini A, Pieruzzi L, Bianchi F, Brozzi F, Ceccarelli C, Viola D, Piaggi P, Vitti P, Pacini F, Elisei R (2013) Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity 131I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. J Clin Endocrinol Metab 98:2693–2700
20. Taieb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fontanier C, Farman-Ara B, De Micco C, Vaillant J, Thomas S, Conte-Devolx B, Loundou A, Auquier P, Henry JF, Mundler O (2009) Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with
recombinant human TSH (rhTSH): a randomized controlled study. Clin Endocrinol 71:115–123

21. Hanscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SL, Haugen BR, Carriere V, Corone C, Reiners C (2006) Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or Hormone withdrawal. J Nucl Med 47:648–650

22. Frigo A, Dardano A, Danese E, Davì MV, Moghetti P, Colato A, Chiesa C, Hindorf C, Flux G, Luster M (2008) EANM dosimetry committee series on standard operational procedures for pre-therapeutic dosimetry. I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 35:1405–1412

23. Borget I, Remy H, Chevalier J, Ricard M, Allyn M, Schlumberger M, De Pouvoirville G (2008) Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur J Nucl Med Mol Imaging 35:1457–1463

24. Tu J, Wang S, Huo Z, Lin Y, Li X, Wang S (2014) Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis. Radiother Oncol 110:25–30

25. Doi SA, Woodhouse NJ (2000) Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin Endocrinol (Oxf) 52:765–773

26. Hackshaw A, Harmer C, Mallick U, Haq M, Franklin JA (2007) 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab 92:28–38

27. Rosario PW, Reis JS, Barroso AL, Rezende LL, Padrao EL, Fagundes TA (2004) Efficacy of low and high 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake. Nucl Med Commun 25:1077–1081

28. Bal C, Padhy AK, Jana S, Pant GS, Basu AK (1996) Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 77:2574–2580

29. Creutzig H (1987) High or low dose radioiodine ablation of thyroid remnants? Eur J Nucl Med 12:99–102

30. Johansen K, Woodhouse NJ, Odugbesan O (1973) Comparison of MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med 32:252–254

31. Pilli T, Brianzoni E, Capocci F, Castagna MG, Fattori S, Poggiu A, Rossi G, Ferretti F, Guarino E, Burroni L, Vattimo A, Cipri C, Pacini F (2007) A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 92:3542–3546

32. Maenpaa HO, Heikkonen J, Vaaalvira L, Tenhunen M, Joensuu H (2008) Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS One 3:e1885

33. Castagna MG, Cevenini G, Theodoropoulos A, Maino F, Memmo S, Cipri C, Belardini V, Brianzoni E, Pacini F (2013) Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. Eur J Endocrinol 169:23–29

34. Franzius C, Dietlein M, Biermann M, Frühwald M, Linden T, Buesky P, Reiners C, Schober O (2007) Procedure guideline for radioiodine therapy and 131iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer. Nuklearmedizin 46:224–231

35. Jarzab B, Handkiewicz-Junak D, Wloch J (2005) Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocr Relat Cancer 12:773–803

36. Lassmann M, Hanscheid H, Chiesa C, Hindorf C, Flux G, Luster M (2008) EANM dosimetry committee series on standard operational procedures for pre-therapeutic dosimetry. I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 35:1405–1412

37. Oliynyk V, Epshtein O, Sovenko T, Tronko M, Elisei R, Pacini F, Pinchera A (2001) Post-surgical ablation of thyroid residues with radioiodine in Ukrainian children and adolescents affected by post-chernobyl differentiated thyroid cancer. J Endocrinol Invest 24:445–447

38. Van Nostrand D, Moreau S, Bandaru VV, Atkins F, Chennupati S, Mete M, Burman K, Wartofsky L (2010) 124I positron emission tomography versus (131I) planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer. Thyroid 20:879–883

39. Muratet JP, Giraud P, Daver A, Minier JF, Gamelin E, Larra F (1997) Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma. J Nucl Med 38:1362–1368

40. Leger AF, Pellans M, Dagoussset F, Chevalier A, Keller I, Clerc J (2005) A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments. Br J Radiol 78:428–432

41. Park HM, Park YH, Zhou XH (1997) Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma. Thyroid 7:277–280

42. Hilditch TE, Dempsey MF, Bolster AA, McMenemy RM, Reed NS (2002) Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. Eur J Nucl Med Mol Imaging 29:783–788

43. McMenemy RM, Hilditch TE, Dempsey MF, Reed NS (2001) Thyroid stunning after (131)I diagnostic whole body scanning. J Nucl Med 42:986–987

44. Silverstein EB (2007) Comparison of outcomes after (123)I versus (131)I pre ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nucl Med 48:1043–1046

45. Verburg FA, Verkooijen RB, Stokkel MP, Van Isselt JW (2009) The success of I131 ablation in thyroid carcinoma is significantly reduced after a diagnostic activity of 40 MBq I131. Nuklearmedizin 48:138–142

46. Robenshtok E, Grewal RK, Fish S, Sabra M, Thyroid Tuttle RM (2013) A low postoperative nonstimulated serum thyroglobulin level does not exclude the presence of radioactive iodine avid metastatic foci in intermediate-risk differentiated thyroid cancer patients. Thyroid 23:436–442

47. Rosario PW, Xavier AC, Thyroid Calsolari MR (2011) Value of post-operative radioiodine in patients with differentiated thyroid cancer and low risk of recurrence. Thyroid 21:49–53

48. Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim SC, Hong SJ, Shong YK (2005) Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 90:1440–1445

49. Castagna MG, Tala Jury HP, Cipri C, Belardini V, Fioravanti C, Pasqui L, Sestini F, Theodoropoulos A, Pacini F (2011) The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma. J Endocrinol Invest 34:e219–e223
50. Maxon HR, Thomas SR, Boehringer A, Drilling J, Sperling MI, Sparks JC, Chen IW (1983) Low iodine diet in I-131 ablation of thyroid remnants. Clin Nucl Med 8:123–126
51. Goslings BM (1975) Proceedings: effect of a low iodine diet on 131-I therapy in follicular thyroid carcinomata. J Endocrinol 64:30P
52. Pluijmen MJ, Eustatia-Rutten C, Goslings BM, Stokkel MP, Arias AM, Diamant M, Romijn JA, Smit JW (2003) Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 58:428–435
53. Lazarus JH (2014) Iodine status in Europe in 2014. Eur Thyroid J 3:3–6
54. Fatourechi V, Hay ID, Mullan BP, Wiseman GA, Eghbali-Fatourechi GZ, Thorson LM, Gorman CA (2000) Are post-therapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid 10:573–577
55. Sherman SI, Tielens ET, Sostre S, Wharam MD Jr, Ladenson PW (1994) Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 78:629–634
56. Souza Rosario PW, Barroso AL, Rezende LL, Padrao EL, Fagundes TA, Penna GC, Purisch S (2004) Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution? Clin Nucl Med 29:795–798
57. Maruoka Y, Abe K, Baba S, Isoda T, Sawamoto H, Tanabe Y, Sasaki M, Honda H (2012) Incremental diagnostic value of SPECT/CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma. Radiology 265(3):902–909